iSAM Funds UK Ltd Acquires 12,666 Shares of Biogen Inc. $BIIB

iSAM Funds UK Ltd grew its holdings in Biogen Inc. (NASDAQ:BIIB) by 279.9% during the third quarter, Holdings Channel reports. The firm owned 17,191 shares of the biotechnology company’s stock after acquiring an additional 12,666 shares during the quarter. iSAM Funds UK Ltd’s holdings in Biogen were worth $2,408,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Empowered Funds LLC increased its holdings in Biogen by 64.9% in the first quarter. Empowered Funds LLC now owns 7,054 shares of the biotechnology company’s stock worth $965,000 after purchasing an additional 2,777 shares in the last quarter. Focus Partners Wealth lifted its stake in Biogen by 172.2% in the first quarter. Focus Partners Wealth now owns 10,173 shares of the biotechnology company’s stock valued at $1,392,000 after buying an additional 6,436 shares during the period. Sivia Capital Partners LLC bought a new position in shares of Biogen during the 2nd quarter worth approximately $216,000. Atria Investments Inc grew its position in shares of Biogen by 14.3% during the 2nd quarter. Atria Investments Inc now owns 1,940 shares of the biotechnology company’s stock worth $244,000 after buying an additional 243 shares during the period. Finally, Allworth Financial LP grew its position in shares of Biogen by 114.3% during the 2nd quarter. Allworth Financial LP now owns 2,179 shares of the biotechnology company’s stock worth $274,000 after buying an additional 1,162 shares during the period. Institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Truist Financial boosted their target price on shares of Biogen from $190.00 to $193.00 and gave the company a “hold” rating in a research report on Monday, February 9th. Tudor Pickering set a $201.00 price target on shares of Biogen in a report on Monday, February 9th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Biogen in a research note on Monday, December 29th. Royal Bank Of Canada upped their price objective on shares of Biogen from $217.00 to $233.00 and gave the company an “outperform” rating in a report on Monday, February 9th. Finally, Mizuho increased their price objective on shares of Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Twelve investment analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $205.04.

Biogen Price Performance

Shares of BIIB opened at $181.55 on Friday. Biogen Inc. has a 12-month low of $110.04 and a 12-month high of $202.41. The business’s fifty day moving average is $184.10 and its 200 day moving average is $166.76. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The stock has a market cap of $26.64 billion, a P/E ratio of 20.61, a P/E/G ratio of 1.47 and a beta of 0.15.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings results on Friday, February 6th. The biotechnology company reported $1.99 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.61 by $0.38. The business had revenue of $2.28 billion during the quarter, compared to the consensus estimate of $2.21 billion. Biogen had a net margin of 13.07% and a return on equity of 12.64%. Biogen’s revenue was down 7.2% compared to the same quarter last year. During the same quarter last year, the firm posted $3.44 EPS. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Sell-side analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Insider Buying and Selling at Biogen

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $199.83, for a total transaction of $531,547.80. Following the completion of the transaction, the insider directly owned 8,043 shares in the company, valued at $1,607,232.69. This trade represents a 24.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 0.18% of the company’s stock.

About Biogen

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.